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Purpose: We propose a novel domain specific loss, which is a differentiable loss function based 
on the dose volume histogram, and combine it with an adversarial loss for the training of deep 
neural networks. In this study, we trained a neural network for generating Pareto optimal dose 
distributions, and evaluate the effects of the domain specific loss on the model performance. 
Methods: In this study, 3 loss functions—mean squared error (MSE) loss, dose volume histogram 
(DVH) loss, and adversarial (ADV) loss—were used to train and compare 4 instances of the neural 
network model: 1) MSE, 2) MSE+ADV, 3) MSE+DVH, and 4) MSE+DVH+ADV. The data for 70 
prostate patients, including the planning target volume (PTV), and the organs-at-risk (OAR) were 
acquired as 96 x 96 x 24 dimension arrays at 5 mm3 voxel size. The dose influence arrays were 
calculated for all 70 prostate patients using a 7 equidistant coplanar beam setup. Using a 
scalarized multicriteria optimization for intensity modulated radiation therapy, 1200 Pareto surface 
plans per patient were generated by pseudo-randomizing the PTV and OAR tradeoff weights. 
With 70 patients, 84,000 plans were generated in total. We divided the data into 54 training, 6 
validation, and 10 testing patients. Each model was trained for a total of 100,000 iterations with a 
batch size of 2. All models used the Adam optimizer with a learning rate of 1 × 10−3.  
Results: Training for 100,000 iterations took 1.5 days (MSE), 3.5 days (MSE+ADV), 2.3 days 
(MSE+DVH), 3.8 days (MSE+DVH+ADV). After training, the prediction time of each model is 
0.052 seconds. Quantitatively, the MSE+DVH+ADV model had the lowest prediction error of 
0.038 (conformation), 0.026 (homogeneity), 0.298 (R50), 1.65% (D95), 2.14% (D98), 2.43% 
(D99). The MSE model had the worst prediction error of 0.134 (conformation), 0.041 
(homogeneity), 0.520 (R50), 3.91% (D95), 4.33% (D98), 4.60% (D99). For both the mean dose 
PTV error and the max dose PTV, Body, Bladder and rectum error, the MSE+DVH+ADV 
outperformed all other models. Regardless of model, all predictions have an average mean and 
max dose error less than 2.8% and 4.2%, respectively. 
Conclusion: The MSE+DVH+ADV model performed the best in these categories, illustrating the 
importance of both human and learned domain knowledge. Expert human domain specific 
knowledge can be the largest driver in the performance improvement, and adversarial learning 
can be used to further capture nuanced attributes in the data. The real-time prediction capabilities 
allow for a physician to quickly navigate the tradeoff space for a patient, and produce a dose 
distribution as a tangible endpoint for the dosimetrist to use for planning. This is expected to 
considerably reduce the treatment planning time, allowing for clinicians to focus their efforts on 
the difficult and demanding cases.  
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I. Introduction 
External beam radiation therapy is one of the major treatments available to cancer patients, with 
major modalities available including intensity modulated radiation therapy (IMRT)1-7 and volume 
modulated arc therapy (VMAT)8-15. IMRT and VMAT have revolutionized the treatment planning 
over the past decades, drastically improving the treatment plan quality and patient outcome. 
However, many tedious and time consuming aspects still exist within the clinical treatment 
planning workflow. In particular, there are two aspects: 1) The dosimetrist must tediously and 
iteratively tune the treatment planning hyperparameters of the fluence map optimization in order 
to arrive at a planner-acceptable dose, and 2) many feedback loops between the physician and 
dosimetrist occur for the physician to provide his comments and judgement on the plan quality, 
until a physician-acceptable dose is finally produced. For a patient, this process can continually 
repeat for many hours to many days, depending on the complexity of the plan. 
Much work over the years has been focused on reducing the treatment complexity by simplifying 
certain aspects in the planning workflow, such as feasibility seeking16, multicriteria optimization 
for tradeoff navigation on the Pareto surface17-19, and other algorithms for performance 
improvements20-26. While effective, these methods still require a large amount of intelligent input 
from the dosimetrist and physician, such as in weight tuning and deciding appropriate dose-
volume constraints and tradeoffs. 
To address this, the field developed machine learning models to predict relevant dosimetric 
endpoints, which can be categorized into 1 of 3 categories: 1) predicting single dose constraint 
points directly, 2) predicting dose volume histograms (DVH), and 3) predicting the 3D dose 
distribution of the plan. With a 3D dose distribution, one can fully reconstruct the DVH, and with 
the DVH, the dose constraints can then be calculated. Many studies focused on either predicting 
dose constraints or the dose volume histogram, eventually forming the backbone of knowledge-
based planning (KBP)27-42. KBP used machine learning techniques and models to predict clinically 
acceptable dosimetric criteria, utilizing a large pool of historical patient plans and information to 
draw its knowledge from. Before the era of deep neural networks, KBP’s efficacy was heavily 
reliant on not only the patient data size and diversity, but also on the careful selection of features 
extracted from the data to be used in the model32-39,42,43. This limited the model to predict small 
dimensional data, such as the DVH or specific dosimetrist criteria. 
With the advancements in deep learning, particularly in computer vision44-46 and convolutional 
neural networks47, many studies have investigated clinical dose distribution prediction using deep 
learning on several sites such as for prostate IMRT48,49, prostate VMAT32, lung IMRT50, head-and-
neck IMRT51-54, head-and-neck VMAT55. In addition to clinical dose prediction, deep learning 
models are capable of accurately generating Pareto optimal dose distributions, navigating the 
various tradeoffs between planning target volume (PTV) dose coverage and organs-at-risk (OAR) 
dose sparing56.  Most of these methods utilize a simple loss function for training the neural 
network—the mean squared error (MSE) loss.  MSE loss is a generalized, domain-agnostic loss 
function that can be applied to many problems in many domains. It’s large flexibility also means 
that it is incapable of driving its performance in a domain-specific manner. 
Mahmood and Babier et al.52-54 investigated the use of adversarial learning for dose prediction. 
Since the development of generative adversarial networks (GAN) by Goodfellow57, adversarial 
loss has been popularized in the deep learning community for many applications. While used 
heavily for generative models, such as GANs, the adversarial loss can be applied to almost any 
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neural network training. The adversarial loss’s emerging success in deep learning application is 
largely due to the discriminator capability to calculate its own feature maps during the training 
process. In essence, the discriminator is learning its own domain knowledge of the problem. 
However, an adversarial framework is not without its issues. The user has little control over what 
kinds of features the discriminator may be learning during the training process. It is possible for 
the discriminator to learn the correct answer for the wrong reason. In addition, careful balancing 
of the learning between the two networks is essential for preventing catastrophic failure. These 
may affect the overall performance of the prediction framework. 
In 2018, Muralidhar et al.58 proposed a domain adapted loss into their neural network training, in 
order to address deep learning in cases of limited and poor-quality data, which is a problem 
commonly found within the medical field. They found that, by including domain-explicit constraints, 
the domain adapted network model had drastically improved performance over its domain-
agnostic counterpart, especially in the limited, poor-quality data situation. We realize the 
importance of including domain specific losses into the radiation therapy problem of dose 
prediction. We propose the addition of a differentiable loss function based on the dose volume 
histogram (DVH), one of the most important and commonly used metrics in radiation oncology, 
into the training of deep neural networks for volumetric dose distribution prediction. In this study, 
we will train a neural network for generating Pareto optimal dose distributions, and evaluate the 
effects of MSE loss, DVH loss, and adversarial loss on the network’s performance. Pareto optimal 
plans are the solutions to a multicriteria problem with various tradeoffs. In particular, the tradeoff 
lies with the dose coverage of the tumor and the dose sparing of the various critical structures. 
The benefit of such a model is two-fold. First, the physician can interact with the model to 
immediately view a dose distribution, and then adjust some parameters to push the dose towards 
their desired tradeoff in real time. This also allows for the physician to quickly comprehend the 
kinds of the tradeoffs that are feasible for the patient. Second, the treatment planner, upon 
receiving the physician’s desired dose distribution, can quickly generate a fully deliverable plan 
that matches this dose distribution, saving time in tuning the optimization hyperparameters and 
discussing with the physician. 
Because generating Pareto optimal plans for the patient requires for the network to learn how to 
map many dose distributions with tradeoffs from a single anatomy, the neural network must learn 
to differentiate the potentially small nuances between the different doses that may have 
substantial clinical consequences. While these small nuances may not be well reflected in a metric 
such as voxel-wise mean squared error, our own domain metrics can amplify the clinically relevant 
differences. The usage of an adversarial loss can further aid the neural network in learning 
important differences that cannot be easily formulated into a loss function. We believe that training 
a network to generate Pareto optimal dose distribution is well suited for testing the effects of MSE 
loss, DVH loss, and adversarial loss. 
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II. Methods 
II.1. Patient and Pareto Optimal Plan Data 
The data for 70 prostate patients, including the planning target volume (PTV), and the organs-at-
risk (OAR)—body, bladder, rectum, left femoral head, and right femoral head—were acquired as 
96 x 96 x 24 dimension arrays at 5 mm3 voxel size. Ring and skin structures were added as tuning 
structures. The dose influence arrays were calculated for the 70 patients, using a 7 equidistant 
coplanar beam plan IMRT setup. The beamlet size was 2.5 mm2 at 100 cm isocenter. Using this 
dose influence data, we generated IMRT plans that sampled the Pareto surface, representing 
various tradeoffs between the PTV dose coverage and OAR dose sparing. The multicriteria 
objective can be written as: 
 
𝑎𝑟𝑔𝑚𝑖𝑛
𝑥
    {𝑓𝑃𝑇𝑉(𝑥), 𝑓𝑂𝐴𝑅1(𝑥), 𝑓𝑂𝐴𝑅2(𝑥), . . . , 𝑓𝑂𝐴𝑅𝑛𝑂𝐴𝑅
(𝑥)} 
𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜                                  𝑥 ≥ 0                                           
(1) 
where 𝑥 is the fluence map intensities to be optimized. The individual objectives, 𝑓𝑠(𝑥)  ∀𝑠 ∈
{𝑃𝑇𝑉, 𝑂𝐴𝑅𝑢 ∀𝑢 ∈ {1,2, . . . , 𝑛𝑂𝐴𝑅}}, are for the PTV and each of the OARs used in the optimization 
problem, where 𝑛𝑂𝐴𝑅 represents the total number of OARs. The index 𝑠 represents a structure 
used in the optimization, which is the PTV or one of the OARs. For simplicity, we define 𝑆 as the 
set of all structures used in the optimization. In this case, 𝑆 = {𝑃𝑇𝑉, 𝑂𝐴𝑅𝑢 ∀𝑢 ∈ {1,2, . . . , 𝑛𝑂𝐴𝑅}} and 
𝑠 ∈ 𝑆. In radiation therapy, the objective function is formulated with the intention to deliver the 
prescribed dose to the PTV, while minimizing the dose to each OAR. Because to the physical 
aspects of radiation in external beam radiation therapy, it is impossible to deliver to the PTV the 
prescription dose without irradiating normal tissue. In addition, it has been shown that the integral 
dose to the body is similar regardless of the plan59-62, so, in essence, one can only choose how 
to best distribute the radiation in the normal tissue. For example, by reducing the dose to one 
OAR, either the PTV coverage will worsen or more dose will be delivered to another OAR. 
Therefore, we arrive at a multicriteria objective, where there does not exist a single optimal 𝑥∗ that 
would minimize all 𝑓𝑠(𝑥)  ∀𝑠 ∈ 𝑃𝑇𝑉, 𝑂𝐴𝑅.  In this study, we choose to use the ℓ2 -norm to represent 
the objective, 𝑓𝑠(𝑥) =
1
2
‖𝐴𝑠𝑥 − 𝑝𝑠‖2
2. In this formulation, 𝐴𝑠 is the dose influence matrix for a given 
structure, and 𝑝𝑠 is the desired dose for a given structure, assigned as the prescription dose if 𝑠 
is the PTV, and 0 otherwise. Our beamlet-based dose influence matrix was calculated using the 
Eclipse AAA dose calculation engine (Varian Medical Systems, Inc.). This allows for us to linearly 
scalarize the multicriteria optimization problem63, by reformulating it into a single-objective, 
convex optimization problem: 
 
𝑎𝑟𝑔𝑚𝑖𝑛
𝑥
             
1
2
∑ 𝑤𝑠
2‖𝐴𝑠𝑥 − 𝑝𝑠‖2
2
𝑠∈𝑆
                                  
𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜                         𝑥 ≥ 0                                              
(2) 
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Scalarizing the problem required the addition of new hyperparameters, 𝑤𝑠, which are the tradeoff 
weights for each objective function, 𝑓𝑠(𝑥)  ∀𝑠 ∈ 𝑆. By varying 𝑤𝑠 to different values, different Pareto 
optimal solutions can generated by solving the optimization problem. Using an in-house GPU-
based proximal-class first-order primal-dual algorithm, Chambolle-Pock64, we generated many 
pseudo-random plans, by assigning pseudo-random weights to the organs-at-risk. The weight 
assignment fell into 1 of 6 categories as shown in Table 1. 
 
Category Description 
Single organ 
spare 
Bladder 
 𝑤𝑏𝑙𝑎𝑑𝑑𝑒𝑟 = 𝑟𝑎𝑛𝑑(0,1)  
𝑤𝑂𝐴𝑅\𝑏𝑙𝑎𝑑𝑑𝑒𝑟 = 𝑟𝑎𝑛𝑑(0,0.1)  
Rectum 
𝑤𝑟𝑒𝑐𝑡𝑢𝑚 = 𝑟𝑎𝑛𝑑(0,1)  
𝑤𝑂𝐴𝑅\𝑟𝑒𝑐𝑡𝑢𝑚 = 𝑟𝑎𝑛𝑑(0,0.1)  
Lt Fem Head 
𝑤𝑙𝑡 𝑓𝑒𝑚 ℎ𝑒𝑎𝑑 = 𝑟𝑎𝑛𝑑(0,1)  
𝑤𝑂𝐴𝑅\𝑙𝑡 𝑓𝑒𝑚 ℎ𝑒𝑎𝑑 = 𝑟𝑎𝑛𝑑(0,0.1)  
Rt Fem Head 
𝑤𝑟𝑡 𝑓𝑒𝑚 ℎ𝑒𝑎𝑑 = 𝑟𝑎𝑛𝑑(0,1)  
𝑤𝑂𝐴𝑅\𝑟𝑡 𝑓𝑒𝑚 ℎ𝑒𝑎𝑑 = 𝑟𝑎𝑛𝑑(0,0.1)  
Shell 
𝑤𝑠ℎ𝑒𝑙𝑙 = 𝑟𝑎𝑛𝑑(0,1)  
𝑤𝑂𝐴𝑅\𝑠ℎ𝑒𝑙𝑙 = 𝑟𝑎𝑛𝑑(0,0.1)  
Skin 
𝑤𝑠𝑘𝑖𝑛 = 𝑟𝑎𝑛𝑑(0,1)  
𝑤𝑂𝐴𝑅\𝑠𝑘𝑖𝑛 = 𝑟𝑎𝑛𝑑(0,0.1)  
High weights 𝑤𝑠 = 𝑟𝑎𝑛𝑑(0,1)  ∀𝑠 ∈ 𝑂𝐴𝑅  
Medium weights 𝑤𝑠 = 𝑟𝑎𝑛𝑑(0,0.5)  ∀𝑠 ∈ 𝑂𝐴𝑅  
Low  weights 𝑤𝑠 = 𝑟𝑎𝑛𝑑(0,0.1)  ∀𝑠 ∈ 𝑂𝐴𝑅  
Extra low weights 𝑤𝑠 = 𝑟𝑎𝑛𝑑(0,0.05)  ∀𝑠 ∈ 𝑂𝐴𝑅  
Controlled weights 
𝑤𝑏𝑙𝑎𝑑𝑑𝑒𝑟 = 𝑟𝑎𝑛𝑑(0,0.2)  
𝑤𝑟𝑒𝑐𝑡𝑢𝑚 = 𝑟𝑎𝑛𝑑(0,0.2)  
𝑤𝑙𝑡 𝑓𝑒𝑚 ℎ𝑒𝑎𝑑 = 𝑟𝑎𝑛𝑑(0,0.1)  
𝑤𝑟𝑡 𝑓𝑒𝑚 ℎ𝑒𝑎𝑑 = 𝑟𝑎𝑛𝑑(0,0.1)  
𝑤𝑠ℎ𝑒𝑙𝑙 = 𝑟𝑎𝑛𝑑(0,0.1)  
𝑤𝑠𝑘𝑖𝑛 = 𝑟𝑎𝑛𝑑(0,0.3)  
Table 1: Weight assignment categories for the organs at risk. The function 
𝑟𝑎𝑛𝑑(𝑙𝑏, 𝑢𝑏) represents a uniform random number between a lower bound, 𝑙𝑏, and 
an upper bound, 𝑢𝑏. In the high, medium, low, extra low, and controlled weights 
category, the PTV had a 0.05 probability of being assigned 𝑟𝑎𝑛𝑑(0,1) instead of 1. 
 
For each patient, 100 plans of the single organ spare category (bladder, rectum, left femoral head, 
right femoral head, shell, skin) were generated for each critical structure, yielding 600 organ 
sparing plans per patient. To further sample the tradeoff space, another 100 plans of the high, 
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medium, low, and extra low weights category were generated, as well as 200 plans of the 
controlled weights category. In the high, medium, low, extra low, and controlled weights category, 
the PTV had a 0.05 probability of being assigned 𝑟𝑎𝑛𝑑(0,1) instead of 1.The bounds for the 
controlled weights were selected through trial-and-error such that the final plan generated was 
likely to fall within clinically relevant bounds, although it is not necessarily acceptable by a 
physician. In total 1200 plans were generated per patient. With 70 patients, the total number of 
plans generated was 84,000 plans.  
Regarding time for data generation, for each patient, on average it takes 32 minutes to use the 
Eclipse AAA engine to compute beamlet-based dose influence matrices for a 5 beam IMRT plan. 
Using our GPU-accelerated optimization algorithm, it takes roughly 2 seconds to generate 1 
Pareto optimal plan. These exclude the time it takes to identify and gather the original patient 
data, as well as preprocessing steps required for converting the data into python-friendly formats. 
While the optimization of the Pareto optimal plans is fast, the bottleneck is the dose influence 
matrix calculation for each patient. This is an additional motivation for using neural networks, 
which do not require dose influence matrices for predicting Pareto optimal dose distributions. This 
has been shown to yield substantial time savings in generating Pareto optimal plans56. 
 
II.2. Loss Functions 
In this study, 3 loss functions—mean squared error (MSE) loss, dose volume histogram (DVH) 
loss, and adversarial (ADV) loss—were used to train and compare 4 instances of the neural 
network model. The first model used only the voxel-wise MSE loss. The second model’s loss 
function used the MSE loss in conjunction with the ADV loss. The third model used the MSE loss 
in conjunction with the DVH loss. The fourth and last model’s loss function combined MSE, DVH, 
and ADV losses all together. Respectively, the study will denote each variation as MSE, 
MSE+ADV, MSE+DVH, and MSE+DVH+ADV. The following section will describe the ADV and 
DVH losses in detail. 
 
II.1.1. Adversarial Loss 
Our adversarial-style training utilizes a framework similar to that of generative adversarial 
networks (GAN)57, with respect to having another model acting as a discriminator to guide the 
main network to produce a dose distribution close to the real data. The major benefit to this 
approach is that the discriminator is calculating its own features and metrics to distinguish the 
ground truth data and predicted data. Effectively, this is allowing the discriminator to learn its own 
domain knowledge, and then provide feedback to update the main model. For this study, we 
utilized the Least Squares GAN (LSGAN)65 formulation: 
𝑎𝑟𝑔𝑚𝑖𝑛
𝜃𝑁𝐷
   𝐿𝐴𝐷𝑉𝐷 =
1
2
‖𝑁𝐷(𝑦𝑡𝑟𝑢𝑒) − 𝑏‖2
2 +
1
2
‖𝑁𝐷(𝑁𝐺(𝑥)) − 𝑎‖2
2
 
(3) 
𝑎𝑟𝑔𝑚𝑖𝑛
𝜃𝑁𝐺
                      𝐿𝐴𝐷𝑉𝐺 =  
1
2
‖𝑁𝐷(𝑁𝐺(𝑥)) − 𝑐‖2
2
                       
(4) 
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where 𝜃𝑁𝐷 and 𝜃𝑁𝐺  are the trainable weights parameterizing the discriminator, 𝑁𝐷, and 
generator, 𝑁𝐺, respectively. 𝐿𝐴𝐷𝑉𝐷  and 𝐿𝐴𝐷𝑉𝐺 are the loss functions to be minimized with respect 
to 𝜃𝑁𝐷 and 𝜃𝑁𝐺 . The variable 𝑥 represents the input into the generator, 𝑁𝐺, which, because of 
𝐿𝐴𝐷𝑉𝐺 , tries to create data that has a similar distribution to that of 𝑦𝑡𝑟𝑢𝑒, our target data. The 
discriminator tries to distinguish 𝑦𝑡𝑟𝑢𝑒 from the data created from the generator. As per suggestion 
by the LSGAN publication65, to minimize the Pearson Χ2 divergence, we set 𝑎 = −1, 𝑏 = 1, and 
𝑐 = 0. 
 
II.1.2. Dose Volume Histogram Loss 
The DVH is one of the most commonly used metrics in radiation oncology for evaluating the quality 
of a plan, so it is natural to assume that including this metric as part of the loss would be beneficial. 
However, the calculation of the DVH involves non-differentiable operations, which means any loss 
based on it cannot provide a gradient to update the neural network. We propose a differential 
approximation of the DVH, which we define as 𝐷𝑉?̃?. Given a binary segmentation mask, 𝑀𝑠, for 
the 𝑠𝑡ℎ structure, and a volumetric dose distribution, 𝐷, the volume at or above a given dose 
threshold value, 𝑑𝑡, can be approximated as: 
 
𝑣𝑠,𝑑𝑡(𝐷, 𝑀𝑠) =
∑ 𝑆𝑖𝑔𝑚𝑜𝑖𝑑 (
𝑚
𝛽𝑡
(𝐷(𝑖, 𝑗, 𝑘) − 𝑑𝑡)) 𝑀𝑠(𝑖, 𝑗, 𝑘)𝑖,𝑗,𝑘
∑ 𝑀𝑠(𝑖, 𝑗, 𝑘)𝑖,𝑗,𝑘
 
(5) 
where 𝑆𝑖𝑔𝑚𝑜𝑖𝑑(𝑥) =
1
1+𝑒−𝑥
 is the sigmoid function, 𝑚 controls the steepness of the curve, 𝛽𝑡 is 
the bin width of the histogram, and 𝑖, 𝑗, and 𝑘 are the voxel indices for the 3D arrays. The 𝑡 is an 
index for the dose threshold values and bin widths. The total number of thresholds is defined as 
𝑛𝑡, which is also equivalent to the number of bins in 𝐷𝑉?̃?. We also constrain the dose to be 
monotonically increasing with increasing index, 𝑑1 ≤ 𝑑2 ≤ . . . ≤ 𝑑𝑛𝑡. Based on this, the 𝐷𝑉?̃?𝑠 for 
any structure, 𝑠, can then be defined as: 
 
𝐷𝑉𝐻?̃?(𝐷, 𝑀𝑠) = (𝑣𝑠,𝑑1 , 𝑣𝑠,𝑑2 , ⋯ , 𝑣𝑠,𝑑𝑛𝑡 ) 
(6) 
The bin centers and widths are then defined as: 
 
𝑐𝑒𝑛𝑡𝑒𝑟𝑏𝑖𝑛 = (
𝑑1 + 𝑑2
2
,
𝑑2 + 𝑑3
2
, ⋯ ,
𝑑𝑛𝑡 + 𝑑𝑛𝑡+1
2
) 
(7) 
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𝑤𝑖𝑑𝑡ℎ𝑏𝑖𝑛 = (𝛽1, 𝛽2, ⋯ , 𝛽𝑛𝑡) = (𝑑2 − 𝑑1, 𝑑3 − 𝑑2, ⋯ , 𝑑𝑛𝑡+1 − 𝑑𝑛𝑡) 
(8) 
To illustrate Equation 3, we calculated the DVH and the approximated DVH, of varying steepness 
values of 𝑚 = {1,2,4,8}, of a PTV and OAR or an example prostate patient. As demonstrated by 
Figure 1, when the steepness of the curve 𝑚 → ∞, then 𝐷𝑉?̃? → 𝐷𝑉𝐻.  
 
 
Figure 1: DVH and approximated DVH calculations using varying steepness values of 𝑚 =
{1,2,4,8} for an example prostate patient. 
 
Because 𝐷𝑉?̃? is computed using sigmoid, the gradient, 
𝜕𝐷𝑉?̃?(𝐷,𝑀)
𝜕𝐷
= (
𝑣𝑠,𝑑0
𝜕𝐷
,
𝑣𝑠,𝑑1
𝜕𝐷
, ⋯ ,
𝑣𝑠,𝑑𝑛
𝜕𝐷
), can be 
computed, allowing for a loss function utilizing 𝐷𝑉?̃? to be used to update the neural network 
weights. We can then define a mean squared loss of the DVH as: 
 
𝐿𝐷𝑉𝐻(𝐷𝑡𝑟𝑢𝑒 , 𝐷𝑝𝑟𝑒𝑑 , 𝑀) =
1
𝑛𝑠
1
𝑛𝑡
∑ ‖𝐷𝑉𝐻?̃?(𝐷𝑡𝑟𝑢𝑒 , 𝑀𝑠) − 𝐷𝑉𝐻?̃?(𝐷𝑝𝑟𝑒𝑑 , 𝑀𝑠)‖2
2
𝑠
 
(9) 
where 𝐷𝑡𝑟𝑢𝑒 and 𝐷𝑝𝑟𝑒𝑑 are the ground truth and predicted doses, respectively.  While a gradient 
of 𝐿𝐷𝑉𝐻 exists, it is possible that the gradient space is ill-behaved and would be not suitable for 
use. We studied the properties of this approximation using a simple toy example. Letting 𝐷 =
(1,2), The exact DVH and approximate DVH with varying values of 𝑚 = {1,2,4,8} can be 
calculated, shown in Figure 2. 
OAR 
PTV 
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Figure 2: DVH and approximated DVH calculations of toy example for 𝐷 = (1,2). 
 
It can be observed that in this toy example in Figure 2 the approximation is smoother and has 
larger error with smaller 𝑚, which agrees with Figure 1. To investigate the gradient properties of 
the loss using the approximate DVH, we calculated ‖𝐷𝑉𝐻([1,2], 𝑀) − 𝐷𝑉?̃?([𝑖, 𝑗], 𝑀)‖
2
2
 ∀𝑖, 𝑗 ∈ (0,3) 
for 𝑀 = [1,1]. 
 
 
Figure 3: Objective value map of the loss function ‖𝐷𝑉𝐻([1,2], 𝑀) − 𝐷𝑉?̃?([𝑖, 𝑗], 𝑀)‖
2
2
 ∀𝑖, 𝑗 ∈ (0,3) 
for 𝑀 = [1,1]. All versions with varying values of 𝑚 exhibit the same minima. 
 
Figure 3 shows the squared error value of the difference between DVH for the data (1,2) and the 
𝐷𝑉?̃? for the data (𝑖, 𝑗)  ∀𝑖, 𝑗 ∈ (0,3). There are multiple local minima. For our case it is when (𝑖, 𝑗) =
(1,2) 𝑜𝑟 (2,1), since either will produce the same DVH. For higher 𝑚, the local minimas become 
more defined, with steeper gradients surrounding them, an undesirable quality for optimization 
and learning problems. While a lower steepness, 𝑚, may not approximate the DVH as well, the 
loss function involving the 𝐷𝑉?̃? maintains the same local minima, and provides a smoother, and 
more well-behaved gradient than its sharper counterparts. For the remainder of this study, we 
chose to use 𝐷𝑉?̃? with 𝑚 = 1. 
 
  
𝒎 = 𝟖 𝒎 = 𝟒 𝒎 = 𝟐 𝒎 = 𝟏 
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II.3. Model Architecture 
In this study the dose prediction model that was utilized was a U-net style architecture66, and the 
discriminator model was a classification style architecture67,68. 
 
 
 
Figure 4: Deep learning models used in the study. The same U-net architecture is utilized in each 
comparison of MSE, MSE+ADV, MSE+DVH, and MSE+DVH+ADV models. The same 
discriminator architecture is utilized for training the MSE+ADV and MSE+DVH+ADV models. 
Black numbers to the left of the feature blocks represent the current data shape. Red numbers 
above the feature blocks represents the number of features. 
 
Specifically, the models were adjusted to match the data shape. The architectures shown in 
Figure 4 depict the models used in the study. The U-net takes as input a 3 channel tensor that 
consists of, 1) the PTV mask with the value 𝑤𝑃𝑇𝑉 assigned as its non-zero value, 2) the OAR 
masks that include all the OARs respectively assigned their 𝑤𝑂𝐴𝑅𝑠, and 3) the body mask as a 
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binary. The U-net then performs multiple calculations, with max pooling operations to reduce the 
resolution for more global feature calculation, and then upsampling operations to eventually 
restore the image resolution back to the original. Concatenation operations are used to merge the 
local features calculated in the first half of the U-net with the global features calculated at the 
bottom and later half of the U-net. 
The discriminator architecture is of an image classification style network. The goal of the 
discriminator is to learn how to distinguish the optimized dose distributions versus the U-net 
predicted dose distribution. Similar to conditional generative adversarial network framework69, the 
discriminator will additionally take the same input as the U-net. In total, the input data has 4 
channels—3 channels of the U-net’s input and 1 channel of either the optimized or predicted dose 
distribution. As shown in Figure 4, the discriminator goes through a process of convolutions and 
strided convolutions to calculate new feature maps and to reduce the image resolution, 
respectively. It is important to note that the strided convolution is used to reduce one or more of 
the image dimensions by half, but differ in which dimensions are being reduced in order to 
eventually reduce the image to 4 x 4 x4 pixels. For example, the first strided convolution is applied 
to the first 2 image dimensions, reducing the image from 92 x 92 x 20 to 46 x 46 x20, but the last 
strided convolution is reducing the 3rd image dimension. The specific details can be seen in the 
image sizes specified in Figure 4. 
In addition, Group Normalization70 was used in place of Batch Normalization71, which has been 
shown to allow for the models to effectively train on small batch sizes. All activations in the hidden 
layer are rectified linear units (ReLU) activations. Final activations for both the U-net and 
discriminator are linear activations. 
 
II.4. Training and Evaluation 
We first notate the mean squared error loss, dose volume histogram loss, and U-net’s adversarial 
loss as 𝐿𝑀𝑆𝐸(𝑦𝑡 , 𝑦𝑝), 𝐿𝐷𝑉𝐻(𝑦𝑡 , 𝑦𝑝, 𝑀), and 𝐿𝐴𝐷𝑉𝐺(𝑦𝑡 , 𝑦𝑝, 𝑥), where 𝑥 is the input into the U-net 
model, 𝑦𝑡 is the ground truth optimized dose distribution, 𝑦𝑝 is the predicted dose distribution, and 
𝑀 contains the binary segmentation masks. The total objective for training the U-net is then 
defined as: 
 
𝐿𝑇𝑜𝑡𝑎𝑙 =  𝐿𝑀𝑆𝐸(𝑦𝑡 , 𝑦𝑝) + 𝜆𝐷𝑉𝐻𝐿𝐷𝑉𝐻(𝑦𝑡, 𝑦𝑝, 𝑀) + 𝜆𝐴𝐷𝑉𝐿𝐴𝐷𝑉𝐺(𝑦𝑝, 𝑥), 
(10) 
and the objective for training the discriminator is simply 𝐿𝐴𝐷𝑉𝐷 (𝑦, 𝑥), where 𝑦 can either be 𝑦𝑡 or 
𝑦𝑝 for a given training sample. For each study—MSE, MSE+ADV, MSE+DVH, and 
MSE+DVH+ADV—the weightings, 𝜆𝐷𝑉𝐻 and 𝜆𝐴𝐷𝑉, used are shown in Table 2. These were chosen 
by evaluating the order of magnitude of the values that each loss function exhibits for a converged 
model. From previous dose prediction studies and results48,55, we can estimate that the 
𝐿𝑀𝑆𝐸~10
−4 and 𝐿𝐷𝑉𝐻~10
−3 for a converged model. Since we are using least squares GAN 
framework, we estimate the loss 𝐿𝐴𝐷𝑉𝐺  ranges from 10
−1 to 100. Our choice of 𝜆𝐷𝑉𝐻 and 𝜆𝐴𝐷𝑉, 
shown in Table 2, is to have each component of the loss to be within a similar order of magnitude 
for when the model is converged. 
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 𝜆𝐷𝑉𝐻 𝜆𝐴𝐷𝑉 
MSE 0 0 
MSE+ADV 0 0.001 
MSE+DVH 0.1 0 
MSE+DVH+ADV 0.1 0.001 
Table 2: Choices of 𝜆𝐷𝑉𝐻 and 𝜆𝐴𝐷𝑉 for the loss function shown in Equation 10. 
 
We divided the 70 prostate patients into 54 training, 6 validation, and 10 testing patients, yielding 
64,800 training, 7,200 validation, and 12,000 testing plans. For the training that involved 
adversarial loss, the U-net and discriminator would alternate every 100 iterations, to allow for 
some stability in the training and loss. The discriminator was trained to take as input the same 
inputs as the u-net as well as a dose distribution, either from the real training data or from the U-
net’s prediction. With a 0.5 probability, the discriminator would receive either real training data or 
data predicted from the U-net. Each U-net model was trained for a total of 100,000 iterations, 
using a batch size of 2. All models used the Adam optimizer, with a learning rate of 1 × 10−3. All 
training was performed on an NVIDIA 1080 Ti GPU with 11 GB RAM. After training, the model 
with the lowest total validation loss was used to assess the test data. 
All dose statistics will also be reported relative to the relative prescription dose (i.e. the errors are 
reported as a percent of the prescription dose). As clinical evaluation criteria PTV coverage (D98, 
D99), PTV max dose, homogeneity (
𝐷2−𝐷98
𝐷50
), van’t Riet conformation number72 (
(𝑉𝑃𝑇𝑉 ∩ 𝑉100%𝐼𝑠𝑜)
2
𝑉𝑃𝑇𝑉  × 𝑉100%𝐼𝑠𝑜
) 
, the dose spillage 𝑅50 (
𝑉50%𝐼𝑠𝑜
𝑉𝑃𝑇𝑉
), and the structure max and mean doses (Dmax and Dmean) were 
evaluated. Dmax is defined as the dose to 2% of the structure volume, as recommended by the 
ICRU report no 8373.  
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III. Results 
For each model, training for 100,000 iterations took 1.5 days (MSE), 3.5 days (MSE+ADV), 2.3 
days (MSE+DVH), 3.8 days (MSE+DVH+ADV). After training, the prediction time of each U-net 
is the same at 0.052 seconds, since all 4 U-net models in the study are identical in architecture. 
 
Figure 5: Top row: Total validation loss (all relevant losses and loss weightings for a specific 
model are summed are displayed). Bottom row: MSE validation loss (only mean squared error is 
displayed). Left Column: Raw validation losses at each training iteration. Right Column: Smoothed 
validation loss using Savitzky–Golay filter74. 
 
Figure 5 shows the validation losses for each model. The top row shows the total validation loss, 
while the bottom row shows just the mean squared error loss. Overall the loss curve had flattened 
by the end of the 100,000 iterations, indicating that each model converged. The final instances of 
the models chosen for evaluation were the models that performed the best on their respective 
total validation loss. Each model has achieved similar MSE losses, with our chosen models having 
their MSE validation losses at 2.46 × 10-4 (MSE), 2.40 × 10-4 (MSE+ADV), 2.26 × 10-4 
(MSE+DVH), 2.5 × 10-4 (MSE+DVH+ADV). 
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Figure 6: Inputs, optimized dose, and predicted doses for a test patient and a rectum sparing plan. 
Top row: Inputs of the U-net neural network, which include the PTV assigned to its weight (𝑤𝑃𝑇𝑉 =
1 in this example), a binary mask of the body, and the avoidance map containing the remaining 
organs-at-risk assigned to their respective tradeoff weight. Bottom two rows: Optimized and 
predicted dose washes of the Pareto optimal dose. The colorbar shows the doses between 5% 
and 110% of the prescription dose. 
 
Figure 6 shows a comparison of the predictions between each of the 4 models in the study on 1 
example patient and Pareto optimal plan. The “optimized” dose is the ground truth Pareto optimal 
dose that was obtained by solving the optimization problem outlined in Equations 1 and 2. The 
avoidance map is a sum of the critical structures, including a ring and skin tuning structure, with 
their assigned tradeoff weights. The 4 models each take in the top row of Figure 6 as their input, 
and then predict what the Pareto optimal plan should look like. Visually, with the same input, each 
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model produces a strikingly similar dose distribution to the optimized case. The MSE model 
visually did slightly better in sparing the dose in the normal tissue region posterior of the rectum. 
 
 
Figure 7: Dose volume histograms (DVH) of optimized dose distribution (black) and predicted 
dose distributions (various colors) for the same test patient as in Figure 6. Note the x-axis scale 
for the PTV DVH is different. 
 
The DVHs of the dose predictions are more revealing to the dose prediction errors in a clinically 
relevant manner, shown in Figure 7. The two models involving DVH loss (red and green) have 
less error in predicting the dose in the PTV, Body, and Bladder, with respect to its DVH, and 
visually similar predictions for the remaining OARs. Overall, including the domain specific DVH 
based loss has overall improved the model’s dose prediction in regards to the structure’s DVH. 
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Figure 8: Predicion errors for conformation, homogeneity, high dose spillage (R50) and dose 
coverage on the test data. Error bar represents the 99% confidence interval (?̅? ± 2.576 ∗ 𝜎
√𝑛
), 
taken overall all test patients and plans. 
 
Figure 8 shows the errors for several clinical metrics calculated from the predicted dose 
distributions, as compared to that of the optimized dose. The MSE model had the largest 
prediction error of 0.134 (conformation), 0.041 (homogeneity), 0.520 (R50), 3.91% (D95), 4.33% 
(D98), 4.60% (D99). The additional adversarial and DVH losses further improved the prediction 
error, with the MSE+DVH+ADV model having the lowest prediction error of 0.038 (conformation), 
0.026 (homogeneity), 0.298 (R50), 1.65% (D95), 2.14% (D98), 2.43% (D99). The other two 
models, MSE+ADV and MSE+DVH, had errors that were between the other two, with the 
MSE+DVH model’s having less error than MSE+ADV. In terms of these dosimetric criteria, 
including the DVH loss has the best performance, even more than just including adversarial loss. 
Figure 8 is the prime example of how expert human domain knowledge can be used to greatly 
improve the model performance towards the domain relevant criteria. Since comformation, 
homogeneity, dose spillage, and dose coverage all use particular DVH values in its calculation, 
they all improved greatly from usage of 𝐿𝐷𝑉𝐻. Adversarial training for automatic learning of domain 
knowledge can further augment the performance by further capturing details that we did not 
specifically quantify in the loss. It does performs worse on its own, compared to the domain 
knowledge loss, due to the fact that the adversarial learning model does not truly know what is 
important to the user. However, when combined with our own domain knowledge, the 
performance can be maximized. 
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Figure 9: Average error in the mean dose for the PTV and the organs at risk. Error bar represents 
the 99% confidence interval (?̅? ± 2.576 ∗ 𝜎
√𝑛
), taken overall all test patients and plans. 
 
 
Figure 10: Average error in the max dose for the PTV and the organs at risk. Error bar represents 
the 99% confidence interval (?̅? ± 2.576 ∗ 𝜎
√𝑛
), taken overall all test patients and plans. 
 
For both the mean dose PTV error and the max dose PTV, Body, Bladder and rectum error, the 
same improving trend can be observed in the order of the MSE model, MSE+ADV model, 
MSE+DVH model, and MSE+DVH+ADV model shown in Figures 9 and 10. However, there is not 
a clear trend in the mean dose for the OARs, due to the fact that MSE is already designed for 
reducing average errors, making it competitive for the mean dose error performance. There also 
lacks a trend for the max dose point for the femoral heads, which are further away from the PTV 
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and are in the lower dose region that has higher variability in the dose distribution. All predictions 
have very low average mean and max dose errors of less than 2.8% and 4.2%, respectively. 
Due to the large number of test plans we have found that, for conformity, homogeneity, and dose 
coverage (D95, D98, and D99), the MSE+DVH+ADV model had a statistically significant lower 
error than the other predictive models, with the largest p-value=0.007. For mean and max doses 
to the OARs, only 2 comparisons against the MSE+DVH+ADV model were found to be not 
significantly different, which was the mean dose error to the bladder against the MSE model (p-
value=0.894), and the max dose error to the left femoral head against the MSE+DVH model (p-
value=0.409). All other mean and max dose comparisons against the MSE+DVH+ADV had found 
statistically significant differences, with the largest p-value=0.042. 
 
 
IV. Discussion 
To our knowledge, this is the first usage of a domain specific loss function, the DVH loss, for 
volumetric dose distribution prediction in radiation therapy. We compare the performance of deep 
neural networks trained using various loss combinations, including MSE loss, MSE+ADV loss, 
MSE+DVH loss, and MSE+DVH+ADV. Inclusion of the DVH loss had improved the model’s 
prediction in almost every aspect, except for mean dose to the OARs and the max dose the 
femurs. The DVH loss does not directly represent mean or max dose, and thus is not directly 
minimizing these aspects. In addition, MSE loss is inherently designed to minimize average error, 
thus it is not surprising that MSE loss alone is competitive for driving the organ mean dose error 
down, since the additional DVH and ADV losses may have the model focus on aspects other than 
mean error. Regardless of the model, all predictions have an average mean and max dose error 
less than 2.8% and 4.2%, respectively, of the prescription dose for every structure of interest. 
To be specific, the performance of our model improved with respect to our domain relevant 
metrics, because our domain knowledge-based losses are designed to reduce the error in very 
specific areas of the model’s prediction, while focusing less on minimizing error for irrelevant 
metrics. In addition, having multiple losses can have a regularization effect, which can improve 
model generalizability and overall performance on unseen data. However, this does not guarantee 
that the model’s performance will improve in all aspects, as indicated by the competitive organ 
mean dose error with the MSE model, since mean dose error is already heavily related to mean 
squared error.  
Overall, the MSE+DVH+ADV performed the best in most of the categories, particularly the 
conformity, heterogeneity, high dose spillage, and planning target volume (PTV) dose coverage. 
This illustrates the importance of both human and learned domain knowledge. Expert human 
domain specific knowledge can greatly improve the performance of the model, tailoring the 
prediction towards domain relevant aspects. However, by having to explicit formulate this domain 
knowledge into an equation, it is difficult to capture the nuanced aspects of the problem. Using 
adversarial learning can then be used to further augment the model’s performance, since the 
discriminator network can pick out the subtle aspects that the domain specific formulation may 
have missed. 
19 
Due to the non-convexity of both the DVH and ADV losses, as well as the inherent non-convex 
nature of neural networks, the MSE loss was utilized in every variant of the study, acting as the 
initial driving force and guide for the model to reasonably converge before the DVH and/or ADV 
losses began to take effect on the model’s prediction. MSE loss still has many desirable properties 
from an optimization perspective. It is convex and has an extremely well behaved gradient. In 
addition the properties of the squared ℓ2-norm, where ℓ𝑝(𝑥) = √∑ |𝑥|𝑝𝑖
𝑝
, is one of the most 
understood and utilized functions in optimization75. It is not surprising that the previous studies 
achieved the state-of-the-art performance for dose prediction utilizing only MSE loss.  
The final errors were assessed with 12,000 plans from 10 test patients, with varying tradeoff 
combinations. The total large number of plans with the randomization scheme given in Table 1 
gives us confidence that the entire tradeoff space has been reasonably sampled. Theoretically, 
the space can be fully sampled from just using the “high weights” randomization scheme outlined 
in Table 1. However, it would take far more sampling points, since most of the plans deriving from 
this scheme would not be considered even close to clinically acceptable. By including weight 
randomizations in the “Single organ spare” category, we are able to create a particular single-
organ-sparing plan, with varying degrees of sparing through randomization. Furthermore, the 
remaining randomization schemes allow for us to create general plans that are closer to clinical 
relevance than the “high weights” scheme. These effectively allow for us to smooth the tradeoff 
surface between the single-organ-sparing plans, and easily interpolate in between, making the 
total set of 12,000 plans representative of the different obtainable dose distribution. 
The low prediction errors on the test patients signify that the model is capable of reliably 
generating Pareto optimal dose distributions with high accuracy. In addition, the raw prediction 
time of the neural network, including data movement to and from the GPU, is at 0.052 seconds. 
Realistically, with data loading, prediction, DVH calculation, and displaying the dose wash to a 
user, it takes approximately 0.6 seconds. This is still fast enough for real time interaction with the 
model to quickly explore the tradeoff space for a patient. The optimization based approach is 
much slower, first requiring, on average, 32 minutes for dose influence matrix calculation, and 
then 2 seconds for the optimization of each Pareto optimal dose. This allows for us to focus this 
tool towards empowering physicians. Immediately after segmentation of the cancer patient, the 
physician can immediately begin to generate a dose distribution with realistic and patient-specific 
tradeoffs between the PTV and various OARs. Not only does this give the physician a sense of 
the available and achievable tradeoffs, the resulting dose can then be given to a dosimetrist as a 
tangible and physician-preferred endpoint, alongside the other typical planning information 
provided by the physician. Usage of such a model is expected to drastically reduce the treatment 
planning time by reducing the number of feedback loops between the physician and dosimetrist, 
as well as how much the dosimetrist has to iterate through tuning hyperparameters in the fluence 
map optimization. The clinical relevance regarding the predictive improvement of the model—
using MSE+DVH+ADV loses versus using only MSE—on the dosimetric constraints still require 
assessment through a clinical study to be properly quantified. 
The addition of the adversarial loss increases the training time the most for training, since the 
discriminator has to be trained concurrently. The additional DVH loss does slow down the training 
as well, but has a much smaller effect than the adversarial loss. While the training times were 
wildly different, the final trained neural networks all yield the same exact prediction time, due to 
the fact that they have identical network architectures. The network that took the longest training 
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time, MSE+DVH+ADV, took just under 4 days to train, which is still a very reasonable training 
time to prepare a model.  
When training the multiple models, the weights 𝜆𝐷𝑉𝐻 and 𝜆𝐴𝐷𝑉, were chosen to be 0.1 and 0.001, 
respectively, in order to keep the losses at a similar order of magnitude until convergence. In 
general, this technique of assigning the human and learned domain knowledge weightings can 
be performed similarly. First the general loss model—for example, our MSE model—can be run 
first until convergence. The predictions of the general model can be used to assess its current 
loss value and the human domain knowledge metric to obtain orders of magnitude in the error. 
The adversarial model may have different orders of magnitude in its loss depending on the exact 
loss function used, but this may be estimated by bound evaluation of when the discriminator is 
able to perfectly distinguish the real data vs the predicted data and when it is unable to. The 
human and learned domain knowledge weightings can then be assigned by orders of magnitude, 
but some fine-tuning may be necessary depending on the problem to solve. From the clinical 
perspective, by setting the weights 𝜆𝐷𝑉𝐻 and 𝜆𝐴𝐷𝑉, such that the losses operate in a similar order 
of magnitude, we are setting equal importance to the overall general dose distribution (e.g. MSE), 
domain relevant metrics (e.g. DVH), and letting the network itself decide what is important (e.g. 
ADV). However, it may be necessary to fine tune the weightings, putting even more emphasis on 
a particular aspect for tackling a particular problem. 
Since the invention and adoption of intensity modulated radiation therapy, optimization has 
become the backbone of radiation therapy systems. The user will place their ideal dose 
constraints in the system, and an inverse optimization process occurs to solve for the best 
treatment parameters to realize the dose distribution. While today’s cost functions used 
commercially may be different than what is used in this study, the core concepts remain. We have 
our dose constraints, which is simplified in this study to have the PTV treated to prescription dose, 
and to minimize the dose to any organs-at risk. We also have structure importance weightings, 
𝑤𝑠, where increasing this value for particular structure means to more heavily weight the imposed 
dose constraint. Typically, this means to further improve the dose coverage or homogeneity for 
the target, or to further reduce the dose for a particular critical structure. This study can be further 
extended in a future investigation where the optimization problem is replaced with a more complex 
formulation. 
While this study was primarily focused on the evaluation of the DVH, ADV, and MSE losses, the 
final trained models do have their limitations. While these models are capable of generating dose 
distributions on the Pareto surface, it is currently limited to prostate cancer patients with 7 beam 
IMRT. In addition, the predicted dose distributions are not guaranteed to be deliverable, hence 
the current need for heavier dosimetrist involvement in the treatment planning. As a future study, 
we plan to broaden our Pareto optimal dose prediction work by improving our models to predict 
on different cancer sites, to handle a different number and orientation of beams for IMRT, and to 
work on the VMAT modality. In addition we plan to investigate the development of a fully 
automated treatment planning pipeline, starting with the implementation of a robust dose 
mimicking optimization engine, as the threshold-driven optimization for reference-based auto-
planning (TORA) algorithm25, which can be capable of generating a deliverable plan given a dose 
distribution or constraints. We expect such a pipeline would radically reduce the entire treatment 
planning time, especially for simple cases, allowing for the physician and dosimetrist to focus their 
efforts on more challenging patients. 
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V. Conclusion 
In this study, we proposed a novel domain specific loss function, the dose volume histogram 
(DVH) loss, and evaluated its efficacy alongside two other losses, mean squared error (MSE) loss 
and adversarial (ADV) loss. We trained and evaluated four instances of the models with varying 
loss combinations, which included 1) MSE, 2) MSE+ADV, 3) MSE+DVH, 4) MSE+DVH+ADV. We 
found that the models that included the domain specific DVH loss outperformed the models 
without the DVH loss in most of the categories, particularly on the evaluations of conformity, 
heterogeneity, high dose spillage, and planning target volume (PTV) dose coverage. The 
MSE+DVH+ADV model performed the best in these categories, illustrating the importance of both 
human and learned domain knowledge. Expert human domain specific knowledge can be the 
largest driver in the performance improvement, but it is difficult to capture nuanced aspects of the 
problem in an explicit formulation. Adversarial learning can be used to further capture these 
particular subtle attributes as part of the loss. The prediction of Pareto optimal doses can be 
performed in real-time, allowing for a physician to quickly navigate the tradeoff space for a patient, 
and produce a dose distribution as a tangible endpoint for the dosimetrist to use for planning. 
Eventually we plan to develop a fully automated treatment planning system. This is expected to 
considerably reduce the treatment planning time, while improving the treatment planning quality, 
allowing for clinicians to focus their efforts on the difficult and demanding cases. 
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